ASH 2025 | Final analysis of GAIA/CLL13: second-line treatment in CLL after venetoclax-based frontline

So we present here the final analysis of the GAIA trial with a special aspect of the study, namely relapse treatment after patients received either venetoclax plus rituximab or venetoclax plus obinutuzumab or a triple combination of venetoclax, obinutuzumab plus ibrutinib or chemoimmunotherapy. And what we looked at is how was the time then to the next treatment, from the next treatment, so time to third-line treatment, from second-line treatment starting, because we didn’t collect response data, progression-free survival data, but when we look at then the time to the next treatment, we see that using again targeted treatments and these were venetoclax plus CD20 antibody or continuous treatment with BTKi or also venetoclax plus BTKi as a time-limited treatment they all work very well in patients. The only patients who had a really poor outcome were those who received in second-line treatment chemoimmunotherapy. And these data, I think, they are very informative for patients asking already about their other treatment options after frontline. And what the data are confirming is that we probably can use similar regimens again. Unfortunately, so far, the only time-limited regimen approved in relapse CLL is venetoclax plus rituximab, but there is access to clinical trials or other options to use time-limited treatments. Again, in relapse situations, they can be used.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.